Chen C, Veronese L, Yin Y
Division of Clinical Pharmacology, Glaxo Wellcome Research & Development, Greenford, Middlesex, UK.
Br J Clin Pharmacol. 2000 Sep;50(3):193-5. doi: 10.1046/j.1365-2125.2000.00248.x.
The treatment of bipolar disorder often includes use of multiple drug therapies. Lithium is one of the most commonly used treatments, but has a narrow therapeutic window. Lamotrigine, an established antiepileptic drug, is emerging as a potentially important new therapy in the treatment of bipolar disorder. The objective of this two-treatment crossover study was to determine whether lamotrigine affects lithium pharmacokinetics.
Twenty healthy adult men completed the study. Subjects took 2 g lithium gluconate anhydrous every 12 h in the morning and evening for 5 days and in the morning of day 6, with or without 100 mg lamotrigine once daily in the morning for 6 days. Blood and urine samples were collected on day 6 of both treatments to characterize the pharmacokinetics of lithium using noncompartmental methods.
The geometric least-square mean ratio for renal clearance of lithium between the combination treatment and lithium alone treatment was 0.93 (95% confidence interval 0.85-1.02). Both treatments were well tolerated.
Lamotrigine does not cause significant change in the pharmacokinetics of lithium.
双相情感障碍的治疗通常包括使用多种药物疗法。锂盐是最常用的治疗药物之一，但治疗窗较窄。拉莫三嗪作为一种已确立的抗癫痫药物，正逐渐成为双相情感障碍治疗中一种潜在的重要新疗法。这项双治疗交叉研究的目的是确定拉莫三嗪是否会影响锂盐的药代动力学。
20名健康成年男性完成了该研究。受试者在早晨和晚上每12小时服用2克无水葡萄糖酸锂，持续5天，并在第6天早晨，无论有无每天早晨一次100毫克拉莫三嗪的情况下，持续6天。在两种治疗的第6天采集血液和尿液样本，使用非房室模型方法来表征锂盐的药代动力学。
联合治疗与单独使用锂盐治疗相比，锂盐肾清除率的几何最小二乘均值比为0.93（95%置信区间0.85 - 1.02）。两种治疗耐受性均良好。
拉莫三嗪不会引起锂盐药代动力学的显著变化。
